Best GLP-1 for Fatty Liver (2026): The FDA-Approved Pick, Plus the Honest Verdict by Stage

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission from some provider links on this page. Medication eligibility and coverage are determined by licensed clinicians and insurers. Full disclosure →

If you’ve been told you have fatty liver and you’re trying to figure out the best GLP-1 for fatty liver, here’s the part most pages bury: as of August 2025, only one GLP-1 has FDA approval for MASH — the inflamed, progressing form of fatty liver disease — and only for a specific stage of it. That drug is Wegovy injection (semaglutide 2.4 mg weekly). The stage is noncirrhotic MASH with F2–F3 fibrosis. Everything else — Zepbound, Ozempic, Mounjaro, oral GLP-1s, compounded versions — can help your liver indirectly through weight loss, but they aren’t approved as fatty liver treatments. The hard part isn’t picking the drug. It’s figuring out whether you even fit the approved stage.

The Quick Verdict (Before You Scroll)

The best GLP-1 for fatty liver depends on what kind of fatty liver you actually have. If you have confirmed noncirrhotic MASH with F2–F3 fibrosis, Wegovy injection is the clear evidence-first answer because the FDA approved it for that exact condition in August 2025. If you have simple fatty liver (MASLD) with no significant scarring, a GLP-1 that helps you reach 7–10% body-weight loss can meaningfully reduce your liver fat. If you don’t know your stage yet, the answer isn’t a medication — it’s a FibroScan, a FIB-4 score, or a chat with your primary care doctor.

Not sure which row above is you? Take our free 60-second Find My GLP-1 Path quiz → (no email required). It’ll tell you whether your next step is staging, an FDA-approved Wegovy conversation, a weight-loss program, or a specialist referral.

What Is the Best GLP-1 for Fatty Liver?

For a U.S. adult with confirmed noncirrhotic MASH and F2–F3 fibrosis, Wegovy injection (semaglutide 2.4 mg weekly) is the best GLP-1 because it has the FDA approval and the Phase 3 biopsy evidence behind it. For simple MASLD (fat without significant scarring), no single GLP-1 is “best” — the right pick depends on whether you also have obesity, type 2 diabetes, or cardiovascular risk, and whether your insurance plays along.

The FDA approved Wegovy for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis on August 15, 2025 (FDA announcement). That’s the first time any GLP-1 has been approved for fatty liver disease. The approval came through the FDA’s accelerated approval pathway, which means continued approval depends on confirming the benefit in a longer follow-up trial. The label specifies the maintenance dose is 2.4 mg once weekly, with a possible reduction to 1.7 mg once weekly if 2.4 mg isn’t tolerated.

One important detail: the MASH indication applies to Wegovy injection. The Wegovy tablets (Wegovy pill) and the high-dose Wegovy HD 7.2 mg injection have their own approved uses — cardiovascular risk reduction or weight reduction — but are not labeled for MASH. If you’re being treated for the liver, it’s Wegovy injection at the MASH maintenance dose.

Tirzepatide — the active ingredient in Zepbound and Mounjaro — has very strong Phase 2 fatty liver data from the SYNERGY-NASH trial (NEJM, 2024). A Phase 3 outcomes trial is underway. But tirzepatide is not FDA-approved for MASH today. A few aggregator sites incorrectly say it is. They’re wrong.

Then there’s Rezdiffra (resmetirom). It’s FDA-approved for the same MASH F2–F3 population. It’s the first MASH drug ever approved (March 2024) — making Wegovy injection and Rezdiffra the two currently FDA-approved medications for adult MASH with moderate-to-advanced fibrosis. But Rezdiffra is not a GLP-1. It’s a thyroid hormone receptor-beta agonist that works directly in the liver. Your hepatologist will likely bring it up alongside Wegovy.

Don’t Confuse These Terms (Quick Cheat Sheet)

The medical world renamed these conditions in 2023, and most people are still catching up.

MASLD, MASH, NAFLD, NASH: Which Kind of Fatty Liver Do You Actually Have?

You probably have one of three situations: simple MASLD with no significant scarring, MASH with moderate-to-advanced fibrosis (F2–F3), or cirrhosis (F4). The right GLP-1 conversation looks completely different for each. The only way to know which group you’re in is a fibrosis test — usually a FibroScan, a FIB-4 score calculated from your existing lab work, or in some cases a liver biopsy.

Here’s a way to think about it. Imagine three rooms in the same building.

How You Find Out Which Room You’re In

• FIB-4 score. A calculation based on your age, your AST, your ALT, and your platelet count. You can usually get this from labs you already have. Ask your doctor — they may not have run the formula but the numbers are sitting in your chart. The AASLD says a FIB-4 under 1.3 can typically be followed in primary care, while FIB-4 of 1.3 or higher should trigger secondary risk assessment.
• FibroScan (also called VCTE). A painless ultrasound-style test that takes about 10 minutes. Commonly used as the next step after blood-test risk scoring. Available at most gastroenterology practices, hepatology centers, and some imaging facilities.
• ELF (Enhanced Liver Fibrosis) blood test. A newer blood test gaining traction with insurers as an alternative to imaging or biopsy.
• MRE (magnetic resonance elastography). More precise than FibroScan but less widely available.
• Liver biopsy. The reference standard. Reserved for cases where the non-invasive tests don’t clear things up. Most people won’t need one.

For most readers, the practical order looks like this: ask your primary care doctor to calculate your FIB-4 from your existing labs. If that score is intermediate or high, get a FibroScan. If FibroScan is unclear, escalate to MRE or biopsy. That’s the standard hepatology pathway in 2026.

If you have no idea where you stand and your doctor hasn’t mentioned a FibroScan or FIB-4 yet → take our 60-second quiz — we’ll walk you through the questions to ask at your next visit, no email required.

Is Wegovy Actually FDA-Approved for Fatty Liver Disease?

Yes — but the wording matters. On August 15, 2025, the FDA granted accelerated approval to Wegovy injection (semaglutide 2.4 mg weekly) for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis (F2 or F3). It is the first GLP-1 approved for any form of fatty liver disease. It is not a blanket approval for everyone with “fatty liver” on an ultrasound, and the MASH approval applies to Wegovy injection — not the Wegovy pill or Wegovy HD.

What the ESSENCE Phase 3 trial showed

ESSENCE trial: 1,197 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, randomized 2:1 to semaglutide 2.4 mg weekly or placebo for 72 weeks. Sanyal et al., NEJM June 2025.

Who the approval actually covers

• Adults (18+)
• Noncirrhotic MASH (the inflamed, damaging version of fatty liver)
• F2 or F3 fibrosis (moderate or advanced scarring, but not cirrhosis)

Who it doesn’t automatically cover

• People with F0 or F1 (no or mild fibrosis) — they have simple MASLD, not MASH F2–F3
• People with F4 cirrhosis — that’s a specialist conversation
• Children under 18
• Anyone with a personal or family history of medullary thyroid cancer or MEN-2

What the Trials Actually Show: ESSENCE vs. SYNERGY-NASH

The ESSENCE Phase 3 trial of semaglutide and the SYNERGY-NASH Phase 2 trial of tirzepatide both showed strong fatty liver improvements compared to placebo, but they’re not head-to-head and you can’t compare the numbers directly. Semaglutide has carried its benefit across the FDA finish line. Tirzepatide hasn’t yet — a Phase 3 outcomes trial is underway.

ESSENCE — Semaglutide (Wegovy Injection) for MASH F2–F3

• • Trial design: 1,197 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, randomized 2:1 to semaglutide 2.4 mg weekly or placebo for 72 weeks.
• • MASH resolution without worsening fibrosis: 63% vs. 34% placebo.
• • Fibrosis improvement without worsening MASH: 37% vs. 22% placebo.
• • Both endpoints hit simultaneously: 33% vs. 16% placebo.
• • Weight loss: −10.5% vs. −2.0% placebo.

SYNERGY-NASH — Tirzepatide (Zepbound) for MASH F2–F3

• • Trial design: 190 adults; biopsy-confirmed MASH F2/F3; randomized to tirzepatide 5, 10, or 15 mg weekly or placebo for 52 weeks.
• • MASH resolution without worsening fibrosis: 51.8% at 5 mg, 62.8% at 10 mg, 73.3% at 15 mg — vs. 13.2% on placebo.
• • Fibrosis improvement without worsening MASH: 59.1%, 53.3%, 54.2% across doses vs. 32.8% placebo.
• • Weight loss: −10.7%, −13.3%, −15.6% across doses vs. −0.8% placebo.
• • Status: Strong signal. Strong weight loss. But this is Phase 2, not Phase 3. No FDA MASH approval yet.

How Much Weight Loss Actually Changes Your Liver

Most major liver and obesity guidelines agree on three numbers: lose 5% of your body weight and your liver fat starts to drop. Lose 7% and the inflammation of MASH can resolve. Lose 10% or more and you can sometimes see fibrosis improvement.

These are discussion targets, not guarantees — bring them to your clinician.

We can’t pretend a GLP-1 makes lifestyle changes optional. The Mediterranean dietary pattern is the best-supported diet for MASLD across every major guideline. Aerobic plus resistance training. Minimal alcohol. Sleep, blood sugar control, blood pressure control. A GLP-1 makes these dramatically easier. It doesn’t replace them.

Semaglutide vs. Tirzepatide for Fatty Liver: Which Has Better Evidence?

Semaglutide has the stronger regulatory answer because Wegovy injection is FDA-approved for MASH F2–F3 and tirzepatide is not. Tirzepatide has very promising Phase 2 MASH data and produces strong weight loss, but its current FDA labels do not include MASH.

Want more on this exact comparison? We dig into the dose-by-dose tradeoffs on our semaglutide vs. tirzepatide page →

What About Ozempic, Mounjaro, and Zepbound for Fatty Liver?

Ozempic, Mounjaro, and Zepbound can help your liver indirectly — through weight loss and better blood sugar control — but none of them carries Wegovy injection’s MASH indication. Same molecule does not mean same FDA indication.

Ozempic (semaglutide, diabetes dosing)

Same molecule as Wegovy. Approved for type 2 diabetes. Doses run from 0.25 mg up to 2.0 mg weekly. The maintenance MASH dose for Wegovy injection is 2.4 mg — slightly higher than the maximum Ozempic dose. If you have type 2 diabetes and fatty liver, Ozempic absolutely belongs in the conversation with your endocrinologist. Just don’t expect insurance to cover it specifically because of your liver — they’ll cover it for the diabetes.

Mounjaro (tirzepatide, diabetes dosing)

Same molecule as Zepbound. Approved for type 2 diabetes. If you have T2D and fatty liver, Mounjaro often produces strong weight loss and metabolic improvement. The MASH benefit should be discussed as a downstream effect, not a labeled treatment. Same off-label-for-MASH constraint as Zepbound.

Zepbound (tirzepatide, obesity/OSA dosing)

Approved for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Doses run from 2.5 mg to 15 mg weekly. If you have obesity plus fatty liver, Zepbound at the higher doses gives you the trial-tested weight loss that drives liver improvement. Just not on a MASH label.

Where Compounded GLP-1s Fit (and Where They Do Not) for Fatty Liver

Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drugs and are not approved for fatty liver disease. If you have confirmed MASH and F2 or F3 fibrosis, the FDA-approved Wegovy injection pathway is the right answer.

We’re going to be straight with you. This site earns more commission on some compounded programs than on FDA-approved brand-name programs. We’re still telling you that for fatty liver specifically, branded Wegovy injection is the cleaner answer. The FDA hasn’t approved any compounded version of semaglutide or tirzepatide as a finished drug for any condition, let alone MASH. Treating them as interchangeable for a medical condition like MASH would damage your trust and our credibility.

Still trying to figure out whether compounded or branded is the right path? Take our free 60-second matching quiz →

Who Should Not Choose a GLP-1 for Fatty Liver Without Specialist Guidance

Some readers should not treat this as a “click and order online” decision.

• Personal or family history of medullary thyroid cancer or MEN-2. This is a boxed warning. Do not use these drugs.
• History of pancreatitis. Discuss with your doctor before starting.
• Active gallbladder disease. GLP-1s can increase the risk of gallbladder events.
• Severe gastroparesis or other major GI motility problems. GLP-1s slow gastric emptying.
• Pregnancy or trying to get pregnant. GLP-1s are not recommended in pregnancy.
• Taking insulin or sulfonylureas. Risk of hypoglycemia rises.
• Diabetic retinopathy. Rapid blood sugar improvement has been linked to retinopathy complications.
• Cirrhosis (F4). Wegovy injection’s MASH indication doesn’t extend to cirrhosis. Hepatology call.
• Rapidly worsening ALT/AST or jaundice. This needs a doctor’s evaluation, not a telehealth visit.

What to bring to your doctor visit

How to Get the Right GLP-1 for Your Situation: Provider Paths

Four paths cover almost every fatty liver reader.

Path 1 — Confirmed F2–F3 MASH (FDA-Approved On-Label Pathway)

This is the path where the August 2025 Wegovy injection approval actually changes the conversation. With MASH on the label, you have a real shot at insurance coverage specifically because of your liver disease.

Primary recommendation: Ro

Ro’s current publicly listed GLP-1 menu includes Wegovy injection for the MASH-labeled path, plus Wegovy pill, Foundayo, Zepbound KwikPen, and Ozempic. They have a dedicated insurance concierge that handles the prior-authorization process. They offer a free GLP-1 Insurance Coverage Checker. Pricing: $39 first month, then $74/month with annual prepay or $149/month month-to-month. Medication billed separately.

Secondary recommendation: Sesame Care

A marketplace model where you choose the provider. Sesame’s public weight-loss page shows access to branded options including Wegovy, Zepbound, Foundayo, and Ozempic. “Success by Sesame” membership starts at about $59/month with annual subscription. Best fit if you want provider choice and transparent self-pay brand pricing.

Path 2 — Overweight or Obese + Fatty Liver, No Confirmed MASH Yet

You have a fatty liver diagnosis. You haven’t been staged for MASH or fibrosis yet. You also have weight to lose. This is by far the most common reader. The path is get an FDA-approved weight-loss GLP-1 — Wegovy or Zepbound — and let the liver improvement come along with the weight loss. Lose 7–10% and your liver fat drops meaningfully.

Primary: Ro for the same reasons as Path 1 — verified FDA-approved formulary, insurance handling, transparent membership pricing.

Alternative: Hims (men) or Hers (women). After the March 2026 Novo Nordisk partnership announcement, Hims and Hers expanded their access to FDA-approved GLP-1s including Wegovy pen, Wegovy pill, and Ozempic. Strong fit if you want a familiar mainstream telehealth brand — but note this is a weight-loss path, not a MASH-labeled path.

Path 3 — Type 2 Diabetes + Fatty Liver

If you have diabetes, your endocrinologist or PCP is in the best position to pick between Ozempic, Mounjaro, Wegovy, and Zepbound for your situation — because they’re choosing across diabetes control, weight loss, cardiovascular risk, and the liver all at once. Ro is a fine secondary if your local doctor’s wait time is months out.

Path 4 — Cirrhosis, Severe Labs, or Unknown Stage

Will Insurance Cover Wegovy for MASH?

Coverage depends on your plan, your documentation, and your plan’s prior authorization rules. The MASH indication on the Wegovy injection label gives documented F2–F3 patients an on-label coverage argument — but it does not guarantee approval.

Before August 2025, almost every commercial plan treated Wegovy as a weight-loss drug. Now there’s a third reason to ask for coverage: noncirrhotic MASH with F2 or F3 fibrosis — an on-label indication that changes the prior-authorization conversation.

The single most useful action you can take right now — before you book any visit, before you fill out any forms — is a fast coverage check:

What If Insurance Denies Wegovy for MASH?

A denial doesn’t always mean game over. The strongest appeal packets clearly document the MASH diagnosis, fibrosis stage, BMI and comorbidities, prior weight-loss attempts, and why Wegovy injection specifically matches the FDA-approved indication.

Build the Appeal Packet

• Diagnosis wording — specifically “MASH” or “NASH” with F2 or F3 fibrosis, not “fatty liver” or “MASLD”
• Fibrosis staging documentation — FibroScan, MRE, ELF, or biopsy report
• BMI plus comorbidities — type 2 diabetes, hypertension, sleep apnea, cardiovascular disease
• Prior weight-loss attempts — many plans want to see lifestyle attempts and possibly prior medications
• Recent liver labs — ALT, AST, platelets, albumin, bilirubin
• Medical necessity letter from your prescriber citing the FDA approval and your match to the indication
• The FDA approval language itself — quote the indication directly from the label

When Coverage Just Isn’t Going to Happen

• • NovoCare savings program — manufacturer-funded support for eligible patients
• • Self-pay cash discount — Ro’s pricing matches LillyDirect, NovoCare, and TrumpRx for many medications
• • Switch the conversation to a different approved indication — if you have obesity or T2D, those may be covered when the liver alone isn’t
• • Consider Rezdiffra (resmetirom) with your hepatologist — FDA-approved for the same population, may have different coverage rules

For broader cost strategies, see our Wegovy too expensive? guide →

Side Effects and Safety to Know Before Any GLP-1

GLP-1 side effects are dominated by GI events — most common during dose titration and improving with time. Serious risks include pancreatitis, gallbladder disease, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycemia (especially with insulin), and a boxed warning regarding thyroid C-cell tumors based on rodent data.

Common side effects (usually manageable)

• • Nausea — most common, peaks during dose increases, usually improves over weeks
• • Diarrhea, constipation, or both — fiber, hydration, slow titration helps
• • Vomiting — should not be severe or prolonged
• • Fatigue — often related to lower calorie intake
• • Acid reflux/heartburn — slowed gastric emptying contributes

Serious side effects (call your doctor)

• Severe persistent abdominal pain — could be pancreatitis. Don’t wait.
• Sudden severe abdominal pain, right upper quadrant — could be gallbladder
• Severe vomiting and dehydration — risk of kidney injury
• Severe or persistent low blood sugar if also on insulin or sulfonylurea
• Rapid vision changes if you have diabetes
• Severe mood changes or thoughts of self-harm — call your prescriber immediately

What Happens After You Start a GLP-1 for Fatty Liver?

Starting the medication is not the finish line. The first 16 weeks are about safely titrating to your target dose while managing side effects. After that, you and your prescriber monitor weight loss, liver labs, and side effects.

What to call your prescriber about

• • Severe or persistent abdominal pain
• • Severe vomiting preventing eating or drinking
• • Yellowing of skin or eyes
• • Rapidly worsening fatigue
• • Severe mood changes or thoughts of self-harm
• • Signs of low blood sugar (if also on insulin or sulfonylurea)
• • Rapid vision changes (if you have diabetes)
• • Pregnancy or planned pregnancy

What Real Readers Are Worried About

We dug through subreddits, comment threads, and patient forums to figure out what people are actually anxious about. The answers below aren’t medical evidence — they’re voice-of-customer signal.

“GLP-1 for fatty liver? Anyone had success with this? My doctor recommended it but I’m not sure I want to take the plunge.”

“Hopefully, this makes insurance approval easier now.”

The pattern across hundreds of threads is the same: uncertainty isn’t usually about whether GLP-1s work. It’s about whether the searcher’s specific diagnosis qualifies, whether insurance will cooperate, and whether the new MASH/MASLD terminology means anything different from what their doctor told them five years ago. That’s exactly the gap this page exists to close.

What We Actually Verified for This Page

Frequently Asked Questions

Bottom Line: Which GLP-1 Path Should You Take for Fatty Liver?

If you have confirmed adult noncirrhotic MASH with F2–F3 fibrosis, Wegovy injection is the best GLP-1 because it has the FDA approval and the Phase 3 evidence — and Ro is currently the cleanest provider path because of the insurance concierge and free coverage checker. If you have simple fatty liver (MASLD) and weight loss is your goal, Wegovy or Zepbound through Ro, Sesame, Hims, or Hers will help your liver indirectly through weight loss. If you have type 2 diabetes alongside fatty liver, your endocrinologist is the right starting point. If you have cirrhosis, rapidly changing labs, or no idea where you stand, see a hepatologist before doing anything online.

Final Recap

Sources

1. U.S. Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH.’ August 15, 2025. fda.gov
2. Wegovy (semaglutide) prescribing information, 2026 label revision. accessdata.fda.gov
3. Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089–2099. PubMed
4. Loomba R, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. ACG summary
5. Kwo PY, et al. Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology
6. U.S. FDA. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (Rezdiffra). March 14, 2024. fda.gov
7. American Gastroenterological Association. Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of NAFLD. gastro.org
8. American Association for the Study of Liver Diseases. Noninvasive Assessment of Patients with MASLD. aasld.org
9. American Association of Clinical Endocrinology. Patient Guide to MASLD and MASH. aace.com
10. Jayabalan D, et al. The impact of body weight change on liver histology in MASLD: a systematic review and meta-analysis. 2026. Gastroenterology Advisor
11. U.S. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
12. Novo Nordisk. ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM. April 30, 2025. prnewswire.com
13. Eli Lilly. Lilly’s tirzepatide was superior to placebo in MASH resolution. investor.lilly.com

Last verified: May 22, 2026 — By Weight Loss Provider Guide Editorial Team. Provider pricing checked weekly; regulatory facts checked before every major update.